PlainPharmaWatch

CMS Open Payments · Tool

Synthes GmbH vs AstraZeneca AB

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

AstraZeneca AB has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 9,332, versus 99 for the other company. Its single largest recorded recipient represents 1.0% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Synthes GmbH
HHI 99 · top recipient 0.1%
Ranked #1,692 of 1,838 companies by HHI
AstraZeneca AB
HHI 9,332 · top recipient 1.0%
Ranked #162 of 1,838 companies by HHI

Payment Overview

Company A

Synthes GmbH

Total Payments
$2.5M
% of Industry
0.0%
Transactions
2,666
Avg per Transaction
$920.59
Recipients
2,666
Avg per Recipient
$920.59
Payment Types
4
Top Payment Type
Compensation for Faculty or Speaker (Medical Education)
Company B

AstraZeneca AB

Total Payments
$2.5M
% of Industry
0.0%
Transactions
62
Avg per Transaction
$39.6K
Recipients
46
Avg per Recipient
$53.4K
Payment Types
4
Top Payment Type
Compensation for Services Other Than Consulting

Highlighted values indicate the higher figure for each metric.

Total payments compared

Synthes GmbH vs AstraZeneca AB - total reported payments in CMS Open Payments PY2024

Synthes GmbH$2.5MAstraZeneca AB$2.5M

Payment Types Breakdown

Synthes GmbH

Compensation for Faculty or Speaker (Medical Education) $944.1K

38.5%

Travel and Lodging $841.6K

34.3%

Grant $619.0K

25.2%

Food and Beverage $49.7K

2.0%

AstraZeneca AB

Compensation for Services Other Than Consulting $1.5M

61.1%

Consulting Fee $51.7K

2.1%

Food and Beverage $701.19

0.0%

Travel and Lodging $467.61

0.0%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Synthes GmbH

  1. 1

    University Of Washington Med Ctr

    $173,039.95 · 15 txns

  2. 2

    University Of Alabama Hospital

    $74,500.00 · 8 txns

  3. 3

    U Of U Hospitals & Clinics

    $52,500.00 · 3 txns

  4. 4

    Rush University Medical Center

    $43,500.00 · 2 txns

  5. 5

    Cedars-Sinai Medical Center

    $43,000.00 · 3 txns

AstraZeneca AB

  1. 1

    Univ Of Mi Hospitals & Hlth Ctrs

    $1,500,537.00 · 2 txns

  2. 2

    VANITA Ramprakash ARODA

    $7,974.46 · 3 txns

  3. 3

    Antonio Anzueto

    $7,023.96 · 1 txns

  4. 4

    Eric Smith Orwoll

    $6,510.00 · 1 txns

  5. 5

    GEOFFREY L CHUPP

    $5,772.75 · 3 txns

Summary Comparison

Metric Synthes GmbH AstraZeneca AB
Total Payments $2.5M $2.5M
% of Industry Total 0.0% 0.0%
Transaction Count 2,666 62
Avg per Transaction $920.59 $39.6K
Recipient Count 2,666 46
Avg per Recipient $920.59 $53.4K
Payment Type Count 4 4
Top Payment Type Compensation for Faculty or Speaker (Medical Education) Compensation for Services Other Than Consulting

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.